ALCL
4 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Crizotinib Continuation Clinical Study (NCT05160922) | Pfizer | 2021-12-27 |
| CELTIC-1: A Phase 2B Study of Cerdulatinib in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) (NCT04021082) | Portola Pharmaceuticals | 2019-11-15 |
| Study of the Biological Mechanisms Associated With the Immunogenicity in Anaplastic Large Cell Lymphoma ( ALCL ) ALK + (NCT02902874) | Gustave Roussy, Cancer Campus, Grand Paris | 2010-04-21 |
Track ALCL automatically
Every clearance here is in the API, with alerts when new ones post.